Financial Performance - Net loss for Q3 2025 was $20.2 million, or $0.56 per share, compared to a net loss of $23.4 million, or $6.70 per share, in Q3 2024[10]. - Total operating expenses for Q3 2025 were $25.2 million, compared to $24.8 million in Q3 2024[16]. Revenue Generation - Collaboration revenue for Q3 2025 was $2.1 million, compared to no revenue in Q3 2024, driven by a multi-year research collaboration with Novartis[6]. Research and Development - Research and development expenses decreased to $18.5 million in Q3 2025 from $20.0 million in Q3 2024, primarily due to a $13.1 million reduction in azelaprag direct costs[7]. - The company is advancing its oral and parenteral APJ agonist programs, targeting IND submissions in 2026[4]. - BioAge's collaboration with JiKang Therapeutics focuses on a novel APJ agonist nanobody with at least 10-fold greater potency than apelin[4]. - The first participant was dosed in the Phase 1 trial of BGE-102, with initial single ascending dose data expected by year-end 2025[2]. - The company anticipates top-line data for the proof-of-concept clinical trial of BGE-102 in the second half of 2026[3]. Cash Position - As of September 30, 2025, the company had approximately $295.9 million in cash, cash equivalents, and marketable securities, sufficient to fund operations through 2029[11]. Administrative Expenses - General and administrative expenses increased to $6.7 million in Q3 2025 from $4.7 million in Q3 2024, mainly due to higher legal fees and personnel-related expenses[8].
Bioage Labs, Inc.(BIOA) - 2025 Q3 - Quarterly Results